Experimental study reveals extended half-life and reduced immunogenicity of polysialylated streptokinase, suggesting enhanced therapeutic potential for dissolving blood clots.
Key Points
To evaluate the biochemical, immunological, and pharmacokinetic characteristics of recombinant streptokinase conjugated with polysialic acid to overcome short circulation time and high immunogenicity.
Conjugated recombinant streptokinase to 10.0 kDa polysialic acid via reductive amination using an optimized 200:1 molar ratio, 24-hour incubation, and 25°C temperature.
Characterized structural properties, stability, and enzyme kinetics using fluorescence spectroscopy, SDS-PAGE, and MALDI-TOF mass spectrometry.
Assessed comparative biological half-life and relative antibody production between native and polysialylated streptokinase variants.
Formed an SK-10.0 kDa PSA conjugate of 56.5 kDa with increased intrinsic fluorescence, indicating enhanced enzyme stability alongside retained substrate specificity.
Polysialylated streptokinase generated approximately 63.0% less antibody production compared to the native version.
Extended plasma half-life from 0.50 hours for native streptokinase to 2.21 hours for the polysialylated variant, representing a 4.42-fold increase in circulation duration.
Cite This Study
Shahbazmohammadi et al. (2026) studied this question.